BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nuance Pharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Nuance Pharma's drugs run\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05270525-1526@assetmemo.bio
DTSTAMP:20261121T005601Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Ohtuvayre (ensifentrine): Phase 2 readout est. (NCT05270525)
DESCRIPTION:Ohtuvayre (ensifentrine)\, phase 2\, Chronic Obstructive Pulmon
 ary Disease.\nStudy: Effect of Ensifentrine (MK-5884/RPL554) on Sputum Mar
 kers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5
 884-023/RPL554-CO-207)\nEstimated primary completion: 1 March 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ensifentrine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05270525
URL:https://assetmemo.bio/drug/ensifentrine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06559150-1526@assetmemo.bio
DTSTAMP:20261121T005601Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Ohtuvayre (ensifentrine): Phase 2 readout est. (NCT06559150)
DESCRIPTION:Ohtuvayre (ensifentrine)\, phase 2.\nStudy: A Phase II Study of
  Ensifentrine in Non-Cystic Fibrosis Bronchiectasis\nEstimated primary com
 pletion: 24 September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ensifentrine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06559150
URL:https://assetmemo.bio/drug/ensifentrine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874815-1526@assetmemo.bio
DTSTAMP:20261121T005601Z
DTSTART;VALUE=DATE:20290429
DTEND;VALUE=DATE:20290430
SUMMARY:Ohtuvayre (ensifentrine): Phase 3 readout est. (NCT07874815)
DESCRIPTION:Ohtuvayre (ensifentrine)\, phase 3\, Chronic Obstructive Pulmon
 ary Disease.\nStudy: Ensifentrine (MK-5884) Study for the Prevention of Ch
 ronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a 
 History of Moderate or Severe Exacerbations While Receiving Standard of Ca
 re (SOC) (MK-5884-031/RPL554/ENHANCE-3)\nEstimated primary completion: 29 
 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ensifentr
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07874815
URL:https://assetmemo.bio/drug/ensifentrine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
